Basic Stats
| LEI | 5493003EDBXRQRW22O75 |
| CIK | 925741 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioCardia, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 13, 2025 |
Exhibit 99.1 BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology Sunnyvale, Calif. USA, and Utrecht, Netherlands, August 13, 2025 – BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases and CART-Tech, B.V., a provider |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999! BioCardia, Inc. (Exact name of registrant a |
|
| August 11, 2025 |
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results Sunnyvale, Calif. – August 11, 2025 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three a |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 4, 2025 |
Exhibit 99.1 BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter Sunnyvale, Calif. USA – August 4, 2025 - BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases |
|
| July 24, 2025 |
Exhibit 99.1 BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure Sunnyvale, Calif. – July 24, 2025 - BioCardia®, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it submitted its CardiAM |
|
| July 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 16, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 16, 2025 |
Exhibit 99.1 Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction Sunnyvale, Calif. – July 16, 2025 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Mi |
|
| July 15, 2025 |
BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 July 15, 2025 BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 July 15, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549-3561 Attn: Joshua Gorsky Re: BioCardia, Inc. Registration Statement on Form S-3 Filed July 9, 2025 File No. 333-288592 Acceleration Request Requested Date: July 17, 2025 Requested T |
|
| July 15, 2025 |
BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 July 15, 2025 BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 July 15, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549-3561 Attn: Joshua Gorsky Re: BioCardia, Inc. Registration Statement on Form S-3 Filed April 30, 2025 File No. 333-286869 Acceleration Request Requested Date: July 17, 2025 Requested |
|
| July 9, 2025 |
As filed with the Securities and Exchange Commission on July 9, 2025 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No. |
|
| July 9, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) BIOCARDIA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| July 8, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275099 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2023 and the Prospectus Supplements dated December 6, 2023, December 2, 2024, and April 4, 2025) Up to $3,633,730 Common Stock This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplemen |
|
| July 2, 2025 |
Form of Securities Purchase and Registration Rights Agreement Exhibit 4.1 FORM OF SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of June 30, 2025, among BioCardia, Inc., a Delaware corporation (the “Company”), and the several investors set forth on Schedule I attached hereto (each, an “Investor” and, collectively, the “Investors”). WHEREAS, t |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 25, 2025 |
BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System Exhibit 99.1 BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System Sunnyvale, Calif., June 25, 2025 – BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted US Patent No. 12,311,127 titled “Radial and Trans- |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 14, 2025 |
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports First Quarter 2025 Business Highlights and Financial Results Sunnyvale, Calif. – May 14, 2025 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registrant a |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 6, 2025 |
Exhibit 99.1 BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of Wisconsin School of |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 1, 2025 |
Exhibit 99.1 BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure Sunnyvale, California – May 1, 2025 - BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the fir |
|
| April 30, 2025 |
As filed with the Securities and Exchange Commission on April 30, 2025 Registration No. |
|
| April 30, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) BIOCARDIA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| April 23, 2025 |
EX-4.1 2 ex806039.htm EXHIBIT 4.1 Exhibit 4.1 FORM OF SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of April 22, 2025, among BioCardia, Inc., a Delaware corporation (the “Company”), and the several investors set forth on Schedule I attached hereto (each, an “Investor” and, collect |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 15, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 15, 2025 |
Exhibit 99.1 BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to progress the trial to enrollment of 39 participants in the United |
|
| April 11, 2025 |
Exhibit 99.1 BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medic |
|
| April 11, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 4, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275099 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2023 and the Prospectus Supplements dated December 6, 2023 and December 2, 2024) Up to $1,813,844 Common Stock This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 31, 2025 |
BioCardia Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Exhibit 99.1 BioCardia Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT SUNNYVALE, Calif. – March 31, 2025 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that Two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, M |
|
| March 31, 2025 |
Exhibit 99.1 BIOCARDIA PHASE 3 CARDIAMP-HF TRIAL OF NOVEL CARDIAC CELL THERAPY FOR ISCHEMIC HEART FAILURE SHOWS INCREASED SURVIVAL, DECREASED CARDIAC EVENTS, AND IMPROVED QUALITY OF LIFE AT TWO YEARS ● Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance ● Stati |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 26, 2025 |
Amended and Restated Certificate of Incorporation, as amended May 29, 2024 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOCARDIA, INC. BioCardia, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The name of the corporation is BioCardia, Inc. The corporation was originally incorporated under the name “NAM Corporation” and the date of filing the original Certificate of Incorporat |
|
| March 26, 2025 |
Exhibit 19.1 BIOCARDIA, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities Effective as of November 10, 2016 (Updated March 24, 2025) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 1 Insider Trading Compliance Offic |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BIOCARDIA, Inc. (Exact name of registrant as spe |
|
| March 26, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioCardia, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0.001 par value p |
|
| March 26, 2025 |
BioCardia Reports 2024 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports 2024 Business Highlights and Financial Results Sunnyvale, Calif. – March 26, 2025 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exch |
|
| March 26, 2025 |
Exhibit 21.1 Subsidiaries of BioCardia, Inc. Name of Subsidiary. Jurisdiction of Organization BioCardia Lifesciences, Inc. Delaware |
|
| March 10, 2025 |
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System Exhibit 99.1 BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System March 10, 2025 Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial De |
|
| March 10, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 27, 2025 |
Exhibit 99.1 BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions Sunnyvale, Calif., February 27, 2025 (GLOBE NEWSWIRE) - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announ |
|
| February 27, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| February 13, 2025 |
Exhibit 99.1 BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery February |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 27, 2025 |
Exhibit 99.1 BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions Sunnyvale, California – January 27, 2025 - BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-b |
|
| December 17, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| December 17, 2024 |
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family Exhibit 99.1 BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family Sunnyvale, Calif. – December 17, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the commercial availability of its Morph DNA steerable introducer product family, curr |
|
| December 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 4, 2024 |
Exhibit 99.1 BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure Next PMDA Consultation after Review of CardiAMP HF Trial Data Sunnyvale, Calif. – December 4, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the succes |
|
| December 2, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275099 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2023 and the Prospectus Supplement dated December 6, 2023) Up to $1,332,045 Common Stock This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December 6, 2023 (the “Initial |
|
| November 13, 2024 |
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results Sunnyvale, Calif. – November 13, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2024 and filed its quarterly report on Form 10-Q for the three a |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registra |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 28, 2024 |
Exhibit 99.1 BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure Sunnyvale, Calif. – October 28, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the completion of its last protocol specified follow-up v |
|
| September 18, 2024 |
BioCardia Regains Full Compliance with Nasdaq Listing Requirements Exhibit 99.1 BioCardia Regains Full Compliance with Nasdaq Listing Requirements Sunnyvale, Calif. – September 18, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required b |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| September 9, 2024 |
Exhibit 99.1 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules Sunnyvale, Calif. – September 9, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the closing of its upsized public offering with participation from manage |
|
| September 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| September 6, 2024 |
BCDA / BioCardia, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioCardia, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 09060U6006 (CUSIP Number) August 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| September 6, 2024 |
EX-99.1 2 ea021385602ex99-1bio.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agree |
|
| September 3, 2024 |
Form of Warrant to Purchase Shares of Common Stock Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOCARDIA, INC. Warrant Shares: Original Issuance Date: August [ ], 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| September 3, 2024 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOCARDIA, INC. Warrant Shares: Original Issuance Date: August [ ], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 3, 2024 |
Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 August 29, 2024 BioCardia, Inc. Attention: Peter Altman, Chief Executive Officer 320 Soquel Way Sunnyvale, CA 94085 Re: Placement Agency Agreement Dear Mr. Altman: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement |
|
| September 3, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2024, between BioCardia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| August 30, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-281448 and 333-281847 PROSPECTUS 1,377,990 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,022,010 Shares of Common Stock Common Warrants to Purchase Up to 2,400,000 Shares of Common Stock Up to 3,422,010 Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants We are offering, on a best e |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 30, 2024 |
Exhibit 99.1 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules Sunnyvale, Calif. – August 30, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the pricing of its upsized public offering with participation from manageme |
|
| August 30, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-281448 and 333-281847 PROSPECTUS 1,377,990 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,022,010 Shares of Common Stock Common Warrants to Purchase Up to 2,400,000 Shares of Common Stock Up to 3,422,010 Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants We are offering, on a best e |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024. S-1MEF 1 bcda20240829s1mef.htm FORM S-1MEF As filed with the Securities and Exchange Commission on August 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOCARDIA, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 23-2753988 (State or other jurisdiction |
|
| August 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 Registration Statement Under the Securities Act of 1933 (Form Type) BioCardia, Inc. |
|
| August 29, 2024 |
Form of Pre-Funded Warrant in connection with this offering Exhibit 4.7 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOCARDIA, INC. Warrant Shares: Original Issuance Date: August [], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024. As filed with the Securities and Exchange Commission on August 29, 2024. Registration No. 333-281448 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BioCardia, Inc. (Exact name of Registrant as specified in its charter) Delaware 2836 23-2753988 (State or other jurisdiction of incorporation o |
|
| August 29, 2024 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 August 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioCardia, Inc. Registration Statement on Form S-1, as amended File No: 333-281448 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as |
|
| August 29, 2024 |
Form of Common Warrant in connection with this offering Exhibit 4.8 WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOCARDIA, INC. Warrant Shares: Original Issuance Date: August [], 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| August 29, 2024 |
Form of Securities Purchase Agreement Exhibit 10.9 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August [], 2024, between BioCardia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| August 29, 2024 |
Form of Placement Agency Agreement Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 August [], 2024 BioCardia, Inc. Attention: Peter Altman, Chief Executive Officer 320 Soquel Way Sunnyvale, CA 94085 Re: Placement Agency Agreement Dear Mr. Altman: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement |
|
| August 29, 2024 |
EX-FILING FEES 4 ex719934.htm EXHIBIT FILING FEES Exhibit 107 Calculation of Filing Fee Table FORM S-1 Registration Statement Under the Securities Act of 1933 (Form Type) BioCardia, Inc. (Exact Name of the Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Ma |
|
| August 29, 2024 |
August 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Re: BioCardia, Inc. Registration Statement on Form S-1 File No. 333-281448 Acceleration Request Requested Date: August 29, 2024 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securiti |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 21, 2024 |
Exhibit 99.1 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment ● Patented personalized medicine approach for patient dosing for autologous cell therapy ● Expected to meaningfully enhance clinical experience and market opportunity Sunnyvale, Calif. – August 21, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader i |
|
| August 13, 2024 |
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results Sunnyvale, Calif. – August 13, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three a |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registrant as |
|
| August 13, 2024 |
BIOCARDIA, INC. 2016 EQUITY INCENTIVE PLAN (as amended effective May 30, 2024 (the “Effective Date”) Exhibit 99.1 BIOCARDIA, INC. 2016 EQUITY INCENTIVE PLAN (as amended effective May 30, 2024 (the “Effective Date”) 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s business. T |
|
| August 13, 2024 |
AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT Exhibit 99.2 AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amendment to the Change in Control and Severance Agreement (the “Amendment”) is entered into by and between BioCardia, Inc. (the “Company”) and Peter Altman (“Executive”) (together, the “Parties,” or individually, a “Party”). RECITALS WHEREAS, Executive signed the Change in Control and Severance Agreement with the Company on |
|
| August 13, 2024 |
AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT Exhibit 99.3 AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amendment to the Change in Control and Severance Agreement (the “Amendment”) is entered into by and between BioCardia, Inc. (the “Company”) and Peter Altman (“Executive”) (together, the “Parties,” or individually, a “Party”). RECITALS WHEREAS, Executive signed the Change in Control and Severance Agreement with the Company on |
|
| August 9, 2024 |
Amended and Restated Certificate of Incorporation, as amended May 29, 2024, as currently in effect Exhibit 3.1 ARTICLE I The name of the Corporation is BioCardia, Inc. ARTICLE II The purpose of this Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (the “DGCL”). ARTICLE III The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024. As filed with the Securities and Exchange Commission on August 9, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BioCardia, Inc. (Exact name of Registrant as specified in its charter) Delaware 2836 23-2753988 (State or other jurisdiction of incorporation or organization) (Primary S |
|
| August 9, 2024 |
BioCardia 2016 Equity Incentive Plan, as amended Exhibit 4.4 BIOCARDIA, INC. 2016 EQUITY INCENTIVE PLAN (as amended effective May 30, 2024 (the “Effective Date”) 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s business. Th |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 Registration Statement Under the Securities Act of 1933 (Form Type) BioCardia, Inc. |
|
| August 9, 2024 |
Exhibit 10.11 AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amendment to the Change in Control and Severance Agreement (the “Amendment”) is entered into by and between BioCardia, Inc. (the “Company”) and Peter Altman (“Executive”) (together, the “Parties,” or individually, a “Party”). RECITALS WHEREAS, Executive signed the Change in Control and Severance Agreement with the Company on |
|
| August 9, 2024 |
Exhibit 10.10 AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amendment to the Change in Control and Severance Agreement (the “Amendment”) is entered into by and between BioCardia, Inc. (the “Company”) and Peter Altman (“Executive”) (together, the “Parties,” or individually, a “Party”). RECITALS WHEREAS, Executive signed the Change in Control and Severance Agreement with the Company on |
|
| July 30, 2024 |
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family Exhibit 99.1 BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family Sunnyvale, Calif. – July 30, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath. This pro |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 25, 2024 |
Exhibit 99.1 Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure Sunnyvale, Calif. – July 25, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 17, 2024 |
Exhibit 99.1 BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application Sunnyvale, Calif. – July 17, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: |
|
| July 8, 2024 |
Exhibit 99.1 CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction July 8, 2024 MULHOUSE, France, and SUNNYVALE, California USA July 8, 2024 - CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derive |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| June 7, 2024 |
Exhibit 99.1 BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach June 7, 2024 Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 30, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOCARDIA, INC. BioCardia, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is BioCardia, Inc. The Corporation was originally incorporated under the name “NAM Corporation” and the Corporation’s origina |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 21, 2024 |
BioCardia Announces Reverse Stock Split Exhibit 99.1 BioCardia Announces Reverse Stock Split SUNNYVALE, Calif. - May 21, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common s |
|
| May 14, 2024 |
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports First Quarter 2024 Business Highlights and Financial Results Sunnyvale, Calif. – May 14, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registrant a |
|
| May 1, 2024 |
Exhibit 99.1 BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes Sunnyvale, Calif., May 1, 2024 (GLOBE NEWSWIRE) - BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 5, 2024 |
BCDA / BioCardia, Inc. / Frost Gamma Investments Trust - SC 13D/A Activist Investment SC 13D/A 1 tm2411035d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 6)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $.001 per |
|
| April 5, 2024 |
Exhibit 1 Joint Filing Agreement EX-99.1 2 tm2411035d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with res |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 28, 2024 |
BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 March 28, 2024 BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 March 28, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549-3561 Re: BioCardia, Inc. Registration Statement on Form S-3 Filed February 14, 2024 File No. 333-277059 Acceleration Request Requested Date: April 1, 2024 Requested Time: 4:30 p.m. |
|
| March 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioCardia, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0.001 par value p |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results SUNNYVALE, Calif. – March 27, 2024 - BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its annual report on Form 10- |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BIOCARDIA, Inc. (Exact name of |
|
| March 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 27, 2024 |
Exhibit 21.1 Subsidiaries of BioCardia, Inc. Name of Subsidiary. Jurisdiction of Organization BioCardia Lifesciences, Inc. Delaware |
|
| March 27, 2024 |
Exhibit 97.1 Compensation Recovery Policy BIOCARDIA, INC. COMPENSATION RECOVERY POLICY As adopted on October 9, 2023 BioCardia, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Comp |
|
| March 13, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 13, 2024 |
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership Exhibit 99.1 BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership ● Partnership targets heart failure, the leading cause of death and a condition with limited treatment options ● BioCardia’s biotherapeutic delivery system with established safety profile enables minimally invasive transplantation of StemCardia’s off-the-shelf cardiac muscle cells Sunnyvale, California– March 13 , 2 |
|
| March 12, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 12, 2024 |
Exhibit 99.1 BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study SUNNYVALE, Calif. - March 12, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement |
|
| March 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 4, 2024 |
Exhibit 99.1 BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure ● CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction i |
|
| February 27, 2024 |
BCDA / BioCardia, Inc. / Frost Gamma Investments Trust - SC 13D/A Activist Investment SC 13D/A 1 tm247389d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $.001 per s |
|
| February 27, 2024 |
EX-99.1 2 tm247389d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with resp |
|
| February 14, 2024 |
As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. |
|
| February 14, 2024 |
BCDA / BioCardia, Inc. / SATTERFIELD THOMAS A JR - SC 13G/A Passive Investment SC 13G/A 1 d742671dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* BioCardia, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09060U507 (CUSIP Number) December 31, 2 |
|
| February 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) BIOCARDIA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 9, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 9, 2024 |
Exhibit 4.1 FORM OF SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and effective as of February 9, 2024, among BioCardia, Inc., a Delaware corporation (the “Company”), and the several investors set forth on Schedule I attached hereto (each, an “Investor” and, collectively, the “Investors”). WHEREAS |
|
| February 8, 2024 |
Exhibit 99.1 BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA SUNNYVALE, Calif., February 08, 2024 – BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chronic myocardial ischemia as pot |
|
| February 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 6, 2024 |
BCDA / BioCardia, Inc. / Frost Gamma Investments Trust - SC 13D/A Activist Investment SC 13D/A 1 tm245362d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $.001 per s |
|
| February 6, 2024 |
EX-1 2 tm245362d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect |
|
| February 2, 2024 |
BCDA / BioCardia, Inc. / Francis Capital Management, LLC Passive Investment SC 13G/A 1 bcda13gv5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09060U507 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 31, 2024 |
Exhibit 99.1 BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference SUNNYVALE, Calif., January 31, 2024 (GLOBE NEWSWIRE) – BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 3, 2024 |
Exhibit 99.1 BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders Sunnyvale, January 3, 2024 – BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issues the following letter to shareholders: Dear Shareholders, BioCardia completed 2023 with three activ |
|
| December 19, 2023 |
Exhibit 99.1 BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction December 19, 2023 SUNNYVALE, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 18, 2023 |
Exhibit 99.1 BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif. – December 18, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Japan Pharmaceutical and Medical |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 6, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 6, 2023 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT December 6, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BioCardia, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agre |
|
| December 6, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275099 PROSPECTUS SUPPLEMENT (To Prospectus dated December 5, 2023) Up to $2,750,000 Common Stock We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, relating to shares of our common stock, $0.001 par value per share, offered by this prospectus suppl |
|
| December 5, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 1, 2023 |
BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 December 1, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: BioCardia, Inc. Registration Statement on Form S-3 File No. 333-275099 Acceleration Request Requested Date: December 5, 2023 Requested Time: 4:30 p.m., Eastern Time Ladie |
|
| November 29, 2023 |
Exhibit 99.1 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval SUNNYVALE, Calif. - November 29, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 17, 2023 |
2,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-249426 Prospectus Supplement (To Prospectus dated October 20, 2020) 2,000,000 Shares of Common Stock We are offering 2,000,000 shares of our common stock, par value $0.001 per share (“common stock”), to an institutional investor at an offering price of $0.65 per share, pursuant to this prospectus supplement and the accompanying prospe |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| November 16, 2023 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 99.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 16, 2023, between BioCardia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| November 15, 2023 |
BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 November 15, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: BioCardia, Inc. Registration Statement on Form S-3 File No. 333-275099 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on Novemb |
|
| November 14, 2023 |
BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 November 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: BioCardia, Inc. Registration Statement on Form S-3 File No. 333-275099 Acceleration Request Requested Date: November 16, 2023 Requested Time: 4:00 p.m. Ladies and Gentle |
|
| November 14, 2023 |
Exhibit 99.1 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure SUNNYVALE, Calif. - November 14, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phas |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registra |
|
| November 8, 2023 |
BIOCARDIA REPORTS THIRD QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Exhibit 99.1 BIOCARDIA REPORTS THIRD QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. – November 8, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2023 and filed its quarterly report on Form 10-Q for the three and |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 19, 2023 |
Exhibit 4.3 BIOCARDIA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of Terms of |
|
| October 19, 2023 |
As filed with the Securities and Exchange Commission on October 19, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. |
|
| October 19, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) BioCardia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 11, 2023 |
Exhibit 99.1 BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II October 11, 2023 SUNNYVALE, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation o |
|
| September 15, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| September 12, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 6, 2023 |
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs Exhibit 99.1 BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs September 6, 2023 SUNNYVALE, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous CardiAMP cell therapy programs. Based on |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 5, 2023 |
Exhibit 99.1 BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial September 5, 2023 SUNNYVALE, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant X Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BioCardia, Inc. (Exact name of registrant as s |
|
| August 9, 2023 |
BIOCARDIA REPORTS SECOND QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Exhibit 99.1 BIOCARDIA REPORTS SECOND QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. – August 9, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 7, 2023 |
BCDA / BioCardia Inc. / SATTERFIELD THOMAS A JR - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 BioCardia, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09060U507 (CUSIP Number) July 28, 2023 (Date of Event Which Requires Filing of this Statem |
|
| July 24, 2023 |
Exhibit 99.1 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected July 24, 2023 SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent D |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 5, 2023 |
Exhibit 99.1 BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency July 5, 2023 Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 22, 2023 |
BioCardia, Inc. 1,133,141 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-249426 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 20, 2020) BioCardia, Inc. 1,133,141 Shares of Common Stock We are offering 1,133,141 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares of common stock are being sold directly to certain existing inve |
|
| June 21, 2023 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 99.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 21, 2023, between BioCardia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 20, 2023 |
Exhibit 99.1 BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study Sunnyvale, Calif. June 20, 2023 – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that FDA Center for Biologics Evalu |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 8, 2023 |
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan Exhibit 99.1 BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled “Radial and Transendocardial Delivery Catheter” with |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 23, 2023 |
Exhibit 99.1 BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study Sunnyvale, Calif. May 23, 2022 – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeti |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BioCardia, Inc. (Exact name of registrant as |
|
| May 10, 2023 |
BIOCARDIA REPORTS FIRST QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Exhibit 99.1 BIOCARDIA REPORTS FIRST QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. – May 10, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications SUNNYVALE, Calif. – May 9, 2023 – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States P |
|
| May 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 -12-31FY2022 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BIOCARDIA, Inc. ( |
|
| May 1, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOCARDIA, INC. Effective April 30, 2023 TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 4 1.1 REGISTERED OFFICE 4 1.2 OTHER OFFICES 4 ARTICLE II — MEETINGS OF STOCKHOLDERS 4 2.1 PLACE OF MEETINGS 4 2.2 ANNUAL MEETING 4 2.3 SPECIAL MEETING 4 2.4 ADVANCE NOTICE PROCEDURES 5 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 12 2.6 QUORUM 12 2.7 ADJOURNED MEETING; N |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 28, 2023 |
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available Exhibit 99.1 BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available Sunnyvale, Calif. April 28, 2022 – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Execu |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 4, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 4, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies SUNNYVALE, Calif. – April 4, 2023 – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technolog |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION As filed with the Securities and Exchange Commission on March 29, 2023 Registration No. |
|
| March 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioCardia, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0.001 par value p |
|
| March 29, 2023 |
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results Exhibit 99.1 BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results SUNNYVALE, Calif. – March 29, 2023 - BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10- |
|
| March 29, 2023 |
Exhibit 21.1 Subsidiaries of BioCardia, Inc. Name of Subsidiary. Jurisdiction of Organization BioCardia Lifesciences, Inc. Delaware |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BIOCARDIA, Inc. (Exact name of registrant as speci |
|
| March 29, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 29, 2023 |
Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SECOND AMENDMENT TO LICENSE AND DISTRIBUTION AGREEMENT This Second Amendment to License and Distribution Agreement (“2d Amendment”) is made and entered into as of as of t |
|
| March 6, 2023 |
Exhibit 99.1 Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart Function to Previously Non-Functionin |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 13, 2023 |
BCDA / BioCardia Inc / Francis Capital Management, LLC Passive Investment SC 13G/A 1 bcda13gv5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09060U507 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 1, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 1, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytesTM for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients SUNNYVALE, California USA and MULHOUSE, France, February 1, 2023 -BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovas |
|
| January 9, 2023 |
BCDA / BioCardia Inc / Allen Jim L. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 allen20230105sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 09060U507 (CUSIP Number) Peter Altman President and Chief Executive Officer BioCardia, Inc. 320 Soqu |
|
| January 9, 2023 |
BCDA / BioCardia Inc / STERTZER SIMON H - SCHEDULE 13D/A Activist Investment SC 13D/A 1 shst20230105sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 09060U507 (CUSIP Number) Peter Altman President and Chief Executive Officer BioCardia, Inc. 320 Soque |
|
| December 28, 2022 |
BCDA / BioCardia Inc / Frost Gamma Investments Trust - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* BioCardia, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 09060 |
|
| December 22, 2022 |
BioCardia Letter to Shareholders Exhibit 99.1 BioCardia Letter to Shareholders Sunnyvale, December 22, 2022- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders, BioCardia is now advancing four novel cell therapies, with three focused on heart disease, a leading |
|
| December 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 22, 2022 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 0-21419 23-2753988 (State or other jurisdiction of incorporation) (Commission File No |
|
| December 20, 2022 |
December 20, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Re: BioCardia, Inc. Registration Statement on Form S-3 (File No. 333-268862) Acceleration Request Requested Date: Thursday, December 22, 2022 Requested Time: 4:30 P.M. Eastern Standard Time Ladies and Gentlemen: Pursuant to Rule |
|
| December 19, 2022 |
As filed with the Securities and Exchange Commission on December 16, 2022 As filed with the Securities and Exchange Commission on December 16, 2022 Registration No. |
|
| December 19, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) BIOCARDIA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| December 15, 2022 |
Exhibit 4.1 FORM OF SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT This SECURITIES PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into and effective as of December 14, 2022, among BioCardia, Inc., a Delaware corporation (the ?Company?), and the several investors set forth on Schedule I attached hereto (each, an ?Investor? and, collectively, the ?Investors?). WHEREA |
